The Effect of Atorvastatin on Oncogenic miRNAs in Hematological Malignancies
Author Information
Author(s): Hashem Jood, Alsukhni Farah, Abushukair Hassan, Ayesh Mahmoud
Primary Institution: Jordan University of Science and Technology
Hypothesis
The study aims to identify significantly differentially expressed miRNAs and involved regulatory pathways post-atorvastatin treatment in hematological malignancy patients.
Conclusion
Atorvastatin treatment resulted in significant changes in the expression of several oncogenic miRNAs in patients with hematological malignancies.
Supporting Evidence
- 14 out of 95 miRNAs showed significant fold changes post-treatment with atorvastatin.
- Higher expressions of certain miRNAs were associated with better overall survival in leukemia and lymphoma patients.
- Enrichment analysis identified pathways involved in cancer progression that were affected by atorvastatin treatment.
Takeaway
This study looked at how a cholesterol medicine called atorvastatin affects tiny molecules in the blood that can help us understand cancer better.
Methodology
The study involved measuring the expression levels of 95 circulating miRNAs in blood samples from 12 patients before and after a 6-week atorvastatin treatment using qPCR.
Potential Biases
The study was conducted at a single institution, which may limit the generalizability of the findings.
Limitations
The study had a small sample size and did not measure target genes directly, limiting mechanistic insights.
Participant Demographics
The participants included 12 patients with hematological malignancies, with a mean age of 56.3 years and equal gender representation.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website